HRSA
Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models
340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation
Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy
340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing
Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS
Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments